US Stock MarketDetailed Quotes

QNRX Quoin Pharmaceuticals

Watchlist
  • 6.769
  • +0.189+2.86%
Close Apr 30 16:00 ET
  • 6.700
  • -0.068-1.01%
Post 16:11 ET
3.98MMarket Cap-0.10P/E (TTM)

Quoin Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
1.60%9.53M
8.45%2.41M
18.95%2.53M
-5.44%2.14M
-11.43%2.46M
1.30%9.38M
6.32%2.22M
-8.69%2.13M
-15.30%2.26M
27.55%2.78M
Selling and administrative expenses
-2.38%5.93M
-3.64%1.33M
-0.64%1.36M
-1.05%1.62M
-4.06%1.62M
-7.81%6.07M
-5.95%1.39M
-13.63%1.37M
-15.79%1.63M
6.00%1.68M
-General and administrative expense
-2.38%5.93M
-3.64%1.33M
-0.64%1.36M
-1.05%1.62M
-4.06%1.62M
-7.81%6.07M
-5.95%1.39M
-13.63%1.37M
-15.79%1.63M
6.00%1.68M
Research and development costs
8.91%3.6M
28.57%1.07M
54.24%1.17M
-16.92%519.35K
-22.80%842.83K
23.76%3.31M
35.77%832.39K
1.78%758.76K
-13.98%625.1K
85.81%1.09M
Operating profit
-1.60%-9.53M
-8.45%-2.41M
-18.95%-2.53M
5.44%-2.14M
11.43%-2.46M
-1.30%-9.38M
-6.32%-2.22M
8.69%-2.13M
15.30%-2.26M
-27.55%-2.78M
Net non-operating interest income expense
-19.60%558.49K
-31.04%109.33K
-25.47%146.39K
-11.90%165.26K
-9.56%137.51K
212.34%694.61K
96.68%158.55K
128.10%196.43K
187.59K
152.05K
Non-operating interest income
-19.60%558.49K
-31.04%109.33K
-25.47%146.39K
-11.90%165.26K
-9.56%137.51K
625.48%694.61K
96.68%158.55K
1,198.08%196.43K
--187.59K
--152.05K
Other net income (expense)
379.61%7.5K
-268.14%-15.54K
1,397.36%31.73K
93.68%-2.18K
-131.86%-6.51K
-100.54%-2.68K
112.00%9.24K
169.41%2.12K
-34.47K
-95.86%20.43K
Gain on sale of security
379.61%7.5K
-268.14%-15.54K
1,397.36%31.73K
93.68%-2.18K
-131.86%-6.51K
-305.28%-2.68K
112.68%9.24K
169.41%2.12K
---34.47K
-73.55%20.43K
Income before tax
-3.18%-8.96M
-12.75%-2.31M
-21.97%-2.35M
6.31%-1.97M
10.59%-2.33M
7.41%-8.69M
-2.44%-2.05M
36.40%-1.93M
21.03%-2.11M
-54.69%-2.6M
Income tax
Net income
-3.18%-8.96M
-12.75%-2.31M
-21.97%-2.35M
6.31%-1.97M
10.59%-2.33M
7.41%-8.69M
-2.44%-2.05M
36.40%-1.93M
21.03%-2.11M
-54.69%-2.6M
Net income continuous Operations
-3.18%-8.96M
-12.75%-2.31M
-21.97%-2.35M
6.31%-1.97M
10.59%-2.33M
7.41%-8.69M
-2.44%-2.05M
36.40%-1.93M
21.03%-2.11M
-54.69%-2.6M
Minority interest income
Net income attributable to the parent company
-3.18%-8.96M
-12.75%-2.31M
-21.97%-2.35M
6.31%-1.97M
10.59%-2.33M
7.41%-8.69M
-2.44%-2.05M
36.40%-1.93M
21.03%-2.11M
-54.69%-2.6M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-3.18%-8.96M
-12.75%-2.31M
-21.97%-2.35M
6.31%-1.97M
10.59%-2.33M
8.05%-8.69M
-2.44%-2.05M
37.75%-1.93M
21.03%-2.11M
-54.69%-2.6M
Basic earnings per share
80.19%-66.85
83.14%-12.25
75.90%-16.45
81.69%-13.65
72.86%-38.85
79.41%-337.4
58.09%-72.6745
82.71%-68.25
94.53%-74.55
86.42%-143.15
Diluted earnings per share
80.19%-66.85
83.17%-12.25
75.90%-16.45
81.69%-13.65
72.86%-38.85
79.41%-337.4
58.02%-72.8
82.71%-68.25
94.53%-74.55
86.42%-143.15
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
--
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 1.60%9.53M8.45%2.41M18.95%2.53M-5.44%2.14M-11.43%2.46M1.30%9.38M6.32%2.22M-8.69%2.13M-15.30%2.26M27.55%2.78M
Selling and administrative expenses -2.38%5.93M-3.64%1.33M-0.64%1.36M-1.05%1.62M-4.06%1.62M-7.81%6.07M-5.95%1.39M-13.63%1.37M-15.79%1.63M6.00%1.68M
-General and administrative expense -2.38%5.93M-3.64%1.33M-0.64%1.36M-1.05%1.62M-4.06%1.62M-7.81%6.07M-5.95%1.39M-13.63%1.37M-15.79%1.63M6.00%1.68M
Research and development costs 8.91%3.6M28.57%1.07M54.24%1.17M-16.92%519.35K-22.80%842.83K23.76%3.31M35.77%832.39K1.78%758.76K-13.98%625.1K85.81%1.09M
Operating profit -1.60%-9.53M-8.45%-2.41M-18.95%-2.53M5.44%-2.14M11.43%-2.46M-1.30%-9.38M-6.32%-2.22M8.69%-2.13M15.30%-2.26M-27.55%-2.78M
Net non-operating interest income expense -19.60%558.49K-31.04%109.33K-25.47%146.39K-11.90%165.26K-9.56%137.51K212.34%694.61K96.68%158.55K128.10%196.43K187.59K152.05K
Non-operating interest income -19.60%558.49K-31.04%109.33K-25.47%146.39K-11.90%165.26K-9.56%137.51K625.48%694.61K96.68%158.55K1,198.08%196.43K--187.59K--152.05K
Other net income (expense) 379.61%7.5K-268.14%-15.54K1,397.36%31.73K93.68%-2.18K-131.86%-6.51K-100.54%-2.68K112.00%9.24K169.41%2.12K-34.47K-95.86%20.43K
Gain on sale of security 379.61%7.5K-268.14%-15.54K1,397.36%31.73K93.68%-2.18K-131.86%-6.51K-305.28%-2.68K112.68%9.24K169.41%2.12K---34.47K-73.55%20.43K
Income before tax -3.18%-8.96M-12.75%-2.31M-21.97%-2.35M6.31%-1.97M10.59%-2.33M7.41%-8.69M-2.44%-2.05M36.40%-1.93M21.03%-2.11M-54.69%-2.6M
Income tax
Net income -3.18%-8.96M-12.75%-2.31M-21.97%-2.35M6.31%-1.97M10.59%-2.33M7.41%-8.69M-2.44%-2.05M36.40%-1.93M21.03%-2.11M-54.69%-2.6M
Net income continuous Operations -3.18%-8.96M-12.75%-2.31M-21.97%-2.35M6.31%-1.97M10.59%-2.33M7.41%-8.69M-2.44%-2.05M36.40%-1.93M21.03%-2.11M-54.69%-2.6M
Minority interest income
Net income attributable to the parent company -3.18%-8.96M-12.75%-2.31M-21.97%-2.35M6.31%-1.97M10.59%-2.33M7.41%-8.69M-2.44%-2.05M36.40%-1.93M21.03%-2.11M-54.69%-2.6M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -3.18%-8.96M-12.75%-2.31M-21.97%-2.35M6.31%-1.97M10.59%-2.33M8.05%-8.69M-2.44%-2.05M37.75%-1.93M21.03%-2.11M-54.69%-2.6M
Basic earnings per share 80.19%-66.8583.14%-12.2575.90%-16.4581.69%-13.6572.86%-38.8579.41%-337.458.09%-72.674582.71%-68.2594.53%-74.5586.42%-143.15
Diluted earnings per share 80.19%-66.8583.17%-12.2575.90%-16.4581.69%-13.6572.86%-38.8579.41%-337.458.02%-72.882.71%-68.2594.53%-74.5586.42%-143.15
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion------------------

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
CG MED EQUIP.
838810
+29.98%
BEOKA
870199
+29.96%
Shenzhen Bromake New Material
301387
+20.01%
4
Zhejiang Hongchang Electrical Technology
301008
+20.00%
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
+20.00%
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.